AMD
Advanced Micro Devices, Inc.
AMD has the edge over MLAB overall, supported by stronger fundamentals and stronger modeled upside.
MLAB
Mesa Laboratories, Inc.
MLAB offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
AMD Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
AMD's revenue, profitability, cash flow and balance sheet are all currently strong.
MLAB Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Healthy |
MLAB's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
AMD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 39x | $585 | — |
| Cheap | 40x | $182 | -69% |
| Fair | 112x | $514 | -12% |
| Current | 127x | $585 | — |
| Expensive | 206x | $947 | +62% |
Historical ranges are pointers, not guarantees.
AMD's PE is in its fair range at 127x. If earnings grow as analysts expect, today's price would be 39x next year's earnings, in its cheap range.
MLAB PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $135 | — |
| Current | 118x | $135 | — |
| Cheap | 142x | $163 | +20% |
| Fair | 301x | $346 | +156% |
| Expensive | 570x | $656 | +385% |
Historical ranges are pointers, not guarantees.
MLAB has the edge over AMD in the historical PE scenario, which offers more potential upside but is not a forecast.
AMD Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Broad | |
| Low |
AMD has the edge over MLAB on the outlook, with more favorable revenue expectations.
MLAB Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect MLAB's earnings to grow and its profitability to improve, with its revenue holding steady.
AMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $15.05 | +227% |
| Q3 2026 | $4.60 | +127% |
| Q2 2026 | $3.89 | +122% |
| Q1 2026 | $3.05 | +123% |
| Q4 2025 | $2.65 | +165% |
| Q3 2025 | $2.03 | +81% |
| Q2 2025 | $1.75 | +111% |
| Q1 2025 | $1.37 | +99% |
| Q4 2024 | $1.00 | +89% |
AMD has the edge over MLAB on earnings, with more consistent year-over-year improvement.
MLAB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $11.01 | +858% |
| Q3 2026 | $1.15 | +$1.46 |
| Q2 2026 | $0.85 | +$0.98 |
| Q1 2026 | $1.21 | +$1.57 |
| Q4 2025 | $0.65 | +$46.97 |
| Q3 2025 | -$0.31 | +$45.31 |
| Q2 2025 | -$0.13 | +$46.35 |
| Q1 2025 | -$0.36 | +$46.84 |
| Q4 2024 | -$46.32 | -25833% |
MLAB has returned to profit: it earned $1.15 per share over the past year, after losing money the year before.
AMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $13.4B | +45% |
| Q2 2026 | $11.5B | +50% |
| Q1 2026 | $10.3B | +38% |
| Q4 2025 | $10.3B | +34% |
| Q3 2025 | $9.2B | +36% |
| Q2 2025 | $7.7B | +32% |
| Q1 2025 | $7.4B | +36% |
| Q4 2024 | $7.7B | +24% |
AMD has the edge over MLAB on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 21% | +7.4 points |
| Q2 2026 | 17% | +19 points |
| Q1 2026 | 14% | +3.6 points |
| Q4 2025 | 17% | +5.7 points |
| Q3 2025 | 14% | +3.1 points |
| Q2 2025 | -1.7% | -6.4 points |
| Q1 2025 | 11% | +10 points |
| Q4 2024 | 11% | +5.8 points |
AMD has the edge over MLAB on profitability, with a higher operating margin.
MLAB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $62.3M | +2.6% |
| Q2 2026 | $60.1M | +1% |
| Q1 2026 | $63.7M | +2.6% |
| Q4 2025 | $65.1M | +3.6% |
| Q3 2025 | $60.7M | +5% |
| Q2 2025 | $59.5M | +2.4% |
| Q1 2025 | $62.1M | +5.5% |
| Q4 2024 | $62.8M | +18% |
MLAB's revenue has grown year over year for 11 quarters in a row: $62M last quarter, up 2.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | +5.7 points |
| Q2 2026 | 12% | +6.5 points |
| Q1 2026 | 4.3% | +1.9 points |
| Q4 2025 | 12% | +3.1 points |
| Q3 2025 | 7.8% | +1.7 points |
| Q2 2025 | 5.2% | -4.4 points |
| Q1 2025 | 2.4% | +463 points |
| Q4 2024 | 9.2% | +9.3 points |
MLAB's operating margin was 13% last quarter, up 5.7 points from the same quarter a year ago, near the top of its range since 2019.
AMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $554M | -71% |
| Q2 2026 | $1.6B | -9.9% |
| Q1 2026 | $2.6B | +253% |
| Q4 2025 | $2.4B | +118% |
| Q3 2025 | $1.9B | +283% |
| Q2 2025 | $1.7B | +294% |
| Q1 2025 | $727M | +92% |
| Q4 2024 | $1.1B | +351% |
AMD has the edge over MLAB on cash flow, with more consistent year-over-year improvement.
MLAB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.7M | -48% |
| Q2 2026 | $14.2M | +1504% |
| Q1 2026 | $13.5M | +14% |
| Q4 2025 | $18M | +2.2% |
| Q3 2025 | $7.1M | +105% |
| Q2 2025 | $884K | -91% |
| Q1 2025 | $11.9M | -3.6% |
| Q4 2024 | $17.6M | +69% |
MLAB generated $49M in free cash flow over the past year, up 32% from the year before.
AMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +2M shares |
| 1 year | +1.2% | +20M shares |
| 3 years | +2% | +32M shares |
| 5 years | +35% | +431M shares |
| Available history | +40% | +473M shares |
AMD has the edge over MLAB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $221M |
| Q4 2025 | — |
| Q3 2025 | $89M |
| Q2 2025 | $478M |
| Q1 2025 | $749M |
| Q4 2024 | $256M |
AMD has spent almost nothing on buybacks in the past year.
MLAB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +3K shares |
| 1 year | +4.1% | +225K shares |
| 3 years | +6.9% | +373K shares |
| 5 years | +7.8% | +416K shares |
| Available history | +32% | +1.4M shares |
MLAB has 6M diluted shares, up 4.1% from a year ago.
AMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2020 | -1.0x | Net Cash |
| Q1 2020 | -0.8x | Net Cash |
| Q4 2019 | -1.2x | Net Cash |
AMD has more cash than debt.
MLAB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.4x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.7x | Healthy |
| Q4 2025 | 0.9x | Very low |
| Q3 2025 | 1.2x | Healthy |
| Q2 2025 | 1.3x | Healthy |
| Q1 2025 | 1.1x | Healthy |
| Q3 2023 | -1.0x | Net Cash |
MLAB's net debt is about 1.4 years of its operating earnings (EBITDA), up from 1.2 years a year ago.
AMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.3 | Neutral |
| Stochastic | 41.4 | Neutral |
AMD's weekly RSI is 59 (neutral) and its Stochastic is 41 (neutral).
MLAB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.7 | Neutral |
| Stochastic | 72.9 | Neutral |
MLAB's weekly RSI is 65 (neutral) and its Stochastic is 73 (neutral).
AMD PE vs Technology Sector
| Metric | AMD | Sector median | Relative |
|---|---|---|---|
| PE | 127x | 28x | 357% above |
| PE % | 61 | 35 | 26 pts above |
AMD is trading at 127x earnings, a 357% premium to the Technology sector's median of 28x.
MLAB PE vs Technology Sector
| Metric | MLAB | Sector median | Relative |
|---|---|---|---|
| PE | 118x | 28x | 322% above |
| PE % | 12 | 35 | 23 pts below |
MLAB has the edge over AMD on valuation relative to its sector.
AMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $557.2 | 5.1% above |
| 20 week MA | $525.9 | 11% above |
| 50 week MA | $389.7 | 50% above |
| 100 week MA | $266.9 | 119% above |
| 200 week MA | $199.6 | 193% above |
AMD is in an uptrend: it's above all five of its weekly moving averages, and 193% above its 200-week average.
MLAB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $129.6 | 4.4% above |
| 20 week MA | $118.6 | 14% above |
| 50 week MA | $102.2 | 32% above |
| 100 week MA | $101.9 | 33% above |
| 200 week MA | $112.8 | 20% above |
MLAB has climbed back above all five of its weekly moving averages, and it's now 20% above its 200-week average.
AMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $46.2 | $91.8 | +99% |
| 2021 | $91.8 | $146.1 | +59% |
| 2022 | $146.1 | $64.5 | -56% |
| 2023 | $64.5 | $147.4 | +128% |
| 2024 | $147.4 | $125.2 | -15% |
| 2025 | $125.2 | $215.0 | +72% |
| 2026 YTD | $215.0 | $585.3 | +172% |
AMD has the edge over MLAB on returns for 2026, with the stronger performance.
MLAB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $247.3 | $284.8 | +15% |
| 2021 | $284.8 | $328.9 | +15% |
| 2022 | $328.9 | $162.8 | -50% |
| 2023 | $162.8 | $104.8 | -36% |
| 2024 | $104.8 | $133.1 | +27% |
| 2025 | $133.1 | $80.5 | -40% |
| 2026 YTD | $80.5 | $135.2 | +68% |
MLAB is up 68% so far in 2026, after finishing lower in three of the previous six years.